For Joe Maher, it started with a simple question from his doctor on a routine visit - is there anything else?
"I happened to look down on my ankle and purely by a fluke… I said, I've got a mole... kind of as a joke," said Joe.
But things turned serious, when he found out it was skin cancer.
After numerous treatments and clinical trials, Joe turned to something new... Zelboraf. It's a drug that targets a specific gene mutation that exists in about half of melanoma patients.
“Zelboraf was engineered to specifically target this gene and to shut it down, allowing the tumor to shrink,” said Dr. Vinh Chung, with Vanguard Skin Specialists.
Dr. Chung doesn't treat Joe, but he's been following the development of this drug closely. He says the results have been remarkable. But there are concerns, particularly about side effects. Patients on Zelboraf can experience nausea, fatigue, joint aches, skin rashes or even different types of skin cancer.
For Joe, dealing with the side effects is a small price to pay.
“It's a treatment, not a cure,” he said.
He's had stage four melanoma for over three years now and is doing well.
Dr. Chung says - it's important to add that this drug is for advanced cases of melanoma only. And he adds that most skin cancers, including melanoma, are almost always curable, if caught early.
“Early detection, early diagnosis, early treatment,” he said.
Since this drug was just approved last week, there's still no word on how insurance companies may cover this drug. But a six month supply will cost about 56-thousand dollars.
KKTV firmly believes in freedom of speech for all and we are happy to provide this forum for the community to share opinions and facts. We ask that commenters keep it clean, keep it truthful, stay on topic and be responsible. Comments left here do not necessarily represent the viewpoint of KKTV 11 News.
If you believe that any of the comments on our site are inappropriate or offensive, please tell us by clicking “Report Abuse” and answering the questions that follow. We will review any reported comments promptly.powered by Disqus